Edwards Lifesciences Files 8-K

TL;DR

Edwards Lifesciences filed an 8-K on 7/15/24 for routine disclosures.

AI Summary

On July 15, 2024, Edwards Lifesciences Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific new financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and exhibits, which are essential for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any immediate negative or positive material events.

Key Players & Entities

• Edwards Lifesciences Corporation (company) — Registrant
• July 15, 2024 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Irvine, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
• $300 million — s to pay consideration of approximately $300 million in cash at the closing of the acquisiti

Filing Documents

• ew-20240715.htm (8-K) — 33KB
• ainnovalvexexhpressrelease.htm (EX-99.1) — 13KB
• ew45percentblacklrga21-ewla.jpg (GRAPHIC) — 625KB
• 0001099800-24-000066.txt ( ) — 1029KB
• ew-20240715.xsd (EX-101.SCH) — 2KB
• ew-20240715_lab.xml (EX-101.LAB) — 21KB
• ew-20240715_pre.xml (EX-101.PRE) — 12KB
• ew-20240715_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "potential," "predict," "expect," "intend," "guidance," "outlook," "optimistic," "aspire," "confident" or other forms of these words or similar expressions and include, but are not limited to, expectations regarding the completion of the Company's acquisition of Innovalve, including the timing and price thereof. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, may be outside of the Company's control, and may be subject to the satisfaction of certain customary conditions. The Company's forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include, but are not limited to: (i) the Company may be unable to close the acquisition of Innovalve in a timely manner

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDWARDS LIFESCIENCES CORPORATION By: /s/ Linda J. Park Linda J. Park Date: July 15, 2024 Senior Vice President, Associate General Counsel and Corporate Secretary 4

View Full Filing

View this 8-K filing on SEC EDGAR